导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.50% | 2946/4773 |
| 近一周 | -1.89% | 842/5462 |
| 近一月 | -3.81% | 1982/5421 |
| 近一季 | -7.31% | 2357/5209 |
| 近半年 | -4.04% | 2401/4920 |
| 近一年 | -1.07% | 2825/4366 |
| 近两年 | 38.43% | 1964/2954 |
| 近三年 | 20.02% | 1463/2253 |
| 成立以来 | 72.54% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.26% 3096/4961 |
11.19% 2363/5312 |
- - |
- - |
| 2025 | 17.01% 2403/4813 |
-1.14% 2592/3635 |
1.48% 2313/4076 |
16.82% 2597/4524 |
-0.15% 2385/4813 |
| 2024 | 12.19% 1263/3463 |
1.78% 855/2808 |
-1.67% 1091/3014 |
14.92% 1877/3129 |
-2.45% 2085/3463 |
| 2023 | -10.13% 1271/2656 |
3.59% 1163/2280 |
-4.83% 1299/2385 |
-3.20% 865/2515 |
-5.83% 1519/2655 |
| 2022 | -17.16% 555/2207 |
-13.04% 690/1919 |
6.77% 609/2016 |
-11.80% 588/2113 |
1.16% 1362/2208 |
| 2021 | 7.95% 488/1822 |
-2.06% 576/1255 |
8.35% 629/1330 |
-1.35% 519/1466 |
3.11% 473/1822 |
| 2020 | 33.00% 467/1250 |
-7.37% 540/1028 |
14.25% 560/1067 |
11.09% 481/1164 |
13.12% 393/1184 |
| 2019 | 33.84% 422/1092 |
24.79% 495/739 |
-0.21% 229/788 |
0.80% 462/850 |
6.62% 581/918 |
| 2018 | - - |
- - |
- - |
0.35% 153/660 |
-8.86% 109/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 建信MSCI联接C VS. 长安沪深300非周期A(740101) |